Target intelligence / Profile preview

Helper T lymphocyte epitope

Molecular classification
Other (epitope/antigenic peptide, not a protein family, receptor, or classical biomolecule)
01

Overview

A helper T lymphocyte epitope is a short peptide sequence (typically 12–20 amino acids) presented on the surface of antigen-presenting cells by MHC class II molecules and recognized by the T cell receptor on CD4+ helper T cells. Recognition of these epitopes is essential for the initiation and regulation of adaptive immune responses, including antibody production, cellular immunity, and cytokine-mediated signaling. These epitopes are central in vaccine development, as their inclusion in vaccine constructs ensures the activation of helper T cells, enhancing both humoral and cellular immune responses[3][5][7]. The term refers to a class of sequences within antigens rather than a specific molecular target. Selecting or engineering optimal helper T cell epitopes (e.g., PADRE or other synthetic peptides) can greatly influence the immunogenicity and efficacy of vaccines[3][7]. Key clarification: "Helper T lymphocyte epitope" is not a single, well-defined molecule or receptor, but a descriptor for any peptide motif recognized by CD4+ T cells. It is foundational in immunology and vaccine science but does not map to a conventional drug target.

Other names
Helper T cell epitopeHTL epitopeT helper epitopeCD4 T cell epitope
02

Mechanism of action

Antigenic peptide binds to MHC II on antigen-presenting cell MHC II-peptide complex is recognized by T cell receptor on CD4+ T cell CD4+ T cell activation leads to secretion of cytokines and orchestration of immune response

03

Biological functions

Immune response activation (via T cell receptor recognition)Antigen presentationInduction of antibody responses (helping B cells)Induction of cellular immunity (macrophage and cytotoxic T cell activation)
04

Disease associations

Infection (vaccine antigen design)Autoimmune disease (when epitopes are self-peptides)Cancer (cancer vaccine and immunotherapy design)Allergy (if involved in hypersensitivity)Inflammation
05

Safety considerations

Risk of autoimmunity if peptide resembles self-proteinsPotential off-target immune responsesVariable efficacy depending on HLA type

Beyond the preview

Go deeper on Helper T lymphocyte epitope.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helper T lymphocyte epitope.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call